6541 — Tanvex Biopharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapMomentum Trap

Annual income statement for Tanvex Biopharma, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0.3	5.41	22.4	61.4	34.7
Cost of Revenue
Gross Profit	0.143	3.55	-19.3	59.7	8.29
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	2,100	1,605	1,628	2,171	1,391
Operating Profit	-2,100	-1,599	-1,606	-2,109	-1,357
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-2,104	-1,543	-1,641	-2,137	-1,381
Provision for Income Taxes
Net Income After Taxes	-2,104	-1,543	-1,641	-2,137	-1,382
Net Income Before Extraordinary Items
Net Income	-2,104	-1,543	-1,641	-2,137	-1,382
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-2,104	-1,543	-1,641	-2,137	-1,382
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-22.2	-13.7	-13.4	-16.3	-8.9
Dividends per Share